Market Cap
US$16.3b
Last Updated
2021/01/20 00:27 UTC
Data Sources
Company Financials +
Executive Summary
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, autoimmune, and infectious diseases in China. More Details
Rewards
Risk Analysis
Currently unprofitable and not forecast to become profitable over the next 3 years
Snowflake Analysis
Adequate balance sheet with limited growth.
Similar Companies
Share Price & News
How has Zai Lab's share price performed over time and what events caused price changes?
Latest Share Price and Events
Stable Share Price: ZLAB is not significantly more volatile than the rest of US stocks over the past 3 months, typically moving +/- 7% a week.
Volatility Over Time: ZLAB's weekly volatility (7%) has been stable over the past year.
Market Performance
7 Day Return
22.1%
ZLAB
4.5%
US Biotechs
0.3%
US Market
1 Year Return
254.2%
ZLAB
40.6%
US Biotechs
21.1%
US Market
Return vs Industry: ZLAB exceeded the US Biotechs industry which returned 36.8% over the past year.
Return vs Market: ZLAB exceeded the US Market which returned 19.5% over the past year.
Shareholder returns
| ZLAB | Industry | Market | |
|---|---|---|---|
| 7 Day | 22.1% | 4.5% | 0.3% |
| 30 Day | 47.5% | 6.8% | 3.3% |
| 90 Day | 117.1% | 27.2% | 14.2% |
| 1 Year | 254.2%254.2% | 42.9%40.6% | 23.8%21.1% |
| 3 Year | 679.9%679.9% | 28.8%22.1% | 45.0%35.4% |
| 5 Year | n/a | 51.3%39.6% | 127.7%102.3% |
Long-Term Price Volatility Vs. Market
How volatile is Zai Lab's share price compared to the market and industry in the last 5 years?
Simply Wall St News
2 weeks ago | Simply Wall St
Zai Lab Limited (NASDAQ:ZLAB): When Will It Breakeven?1 month ago | Simply Wall St
An Intrinsic Calculation For Zai Lab Limited (NASDAQ:ZLAB) Suggests It's 31% Undervalued2 months ago | Simply Wall St
If You Had Bought Zai Lab (NASDAQ:ZLAB) Stock Three Years Ago, You Could Pocket A 216% Gain TodayValuation
Is Zai Lab undervalued compared to its fair value and its price relative to the market?
29.71x
Price to Book (PB) ratio
Share Price vs. Fair Value
Below Fair Value: ZLAB ($184.69) is trading above our estimate of fair value ($110.36)
Significantly Below Fair Value: ZLAB is trading above our estimate of fair value.
Price To Earnings Ratio
PE vs Industry: ZLAB is unprofitable, so we can't compare its PE Ratio to the US Biotechs industry average.
PE vs Market: ZLAB is unprofitable, so we can't compare its PE Ratio to the US market.
Price to Earnings Growth Ratio
PEG Ratio: Insufficient data to calculate ZLAB's PEG Ratio to determine if it is good value.
Price to Book Ratio
PB vs Industry: ZLAB is overvalued based on its PB Ratio (29.7x) compared to the US Biotechs industry average (4.2x).
Next Steps
Future Growth
How is Zai Lab forecast to perform in the next 1 to 3 years based on estimates from 13 analysts?
55.9%
Forecasted annual earnings growth
Earnings and Revenue Growth Forecasts
Analyst Future Growth Forecasts
Earnings vs Savings Rate: ZLAB is forecast to remain unprofitable over the next 3 years.
Earnings vs Market: ZLAB is forecast to remain unprofitable over the next 3 years.
High Growth Earnings: ZLAB is forecast to remain unprofitable over the next 3 years.
Revenue vs Market: ZLAB's revenue (50.5% per year) is forecast to grow faster than the US market (10.3% per year).
High Growth Revenue: ZLAB's revenue (50.5% per year) is forecast to grow faster than 20% per year.
Earnings per Share Growth Forecasts
Future Return on Equity
Future ROE: ZLAB is forecast to be unprofitable in 3 years.
Next Steps
Past Performance
How has Zai Lab performed over the past 5 years?
-49.9%
Historical annual earnings growth
Earnings and Revenue History
Quality Earnings: ZLAB is currently unprofitable.
Growing Profit Margin: ZLAB is currently unprofitable.
Past Earnings Growth Analysis
Earnings Trend: ZLAB is unprofitable, and losses have increased over the past 5 years at a rate of 49.9% per year.
Accelerating Growth: Unable to compare ZLAB's earnings growth over the past year to its 5-year average as it is currently unprofitable
Earnings vs Industry: ZLAB is unprofitable, making it difficult to compare its past year earnings growth to the Biotechs industry (-10.3%).
Return on Equity
High ROE: ZLAB has a negative Return on Equity (-51.65%), as it is currently unprofitable.
Next Steps
Financial Health
How is Zai Lab's financial position?
Financial Position Analysis
Short Term Liabilities: ZLAB's short term assets ($484.9M) exceed its short term liabilities ($56.6M).
Long Term Liabilities: ZLAB's short term assets ($484.9M) exceed its long term liabilities ($26.2M).
Debt to Equity History and Analysis
Debt Level: ZLAB's debt to equity ratio (0.9%) is considered satisfactory.
Reducing Debt: Insufficient data to determine if ZLAB's debt to equity ratio has reduced over the past 5 years.
Balance Sheet
Cash Runway Analysis
For companies that have on average been loss making in the past we assess whether they have at least 1 year of cash runway.
Stable Cash Runway: ZLAB has sufficient cash runway for more than a year based on its current free cash flow.
Forecast Cash Runway: Insufficient data to determine if ZLAB has enough cash runway if its free cash flow continues to grow or shrink based on historical rates.
Next Steps
Dividend
What is Zai Lab current dividend yield, its reliability and sustainability?
Dividend Yield vs Market
Notable Dividend: Unable to evaluate ZLAB's dividend yield against the bottom 25% of dividend payers, as the company has not reported any recent payouts.
High Dividend: Unable to evaluate ZLAB's dividend yield against the top 25% of dividend payers, as the company has not reported any recent payouts.
Stability and Growth of Payments
Stable Dividend: Insufficient data to determine if ZLAB's dividends per share have been stable in the past.
Growing Dividend: Insufficient data to determine if ZLAB's dividend payments have been increasing.
Current Payout to Shareholders
Dividend Coverage: Insufficient data to calculate payout ratio to determine if its dividend payments are covered by earnings.
Future Payout to Shareholders
Future Dividend Coverage: No need to calculate the sustainability of ZLAB's dividend in 3 years as they are not forecast to pay a notable one for the US market.
Next Steps
Management
How experienced are the management team and are they aligned to shareholders interests?
2.8yrs
Average management tenure
CEO
Samantha Du (54 yo)
7yrs
Tenure
Dr. Ying Du, also known as Samantha, Ph.D., serves as Founding Managing Director at Quan Capital. She serves as Venture Partner at Sequoia Capital China. Dr. Du serves as an adjunct professor at Fudan Univ...
Leadership Team
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 7yrs | no data | 1.21% $ 196.0m | |
| President | 4yrs | no data | 0.33% $ 54.4m | |
| Chief Financial Officer | 2.83yrs | no data | 0.068% $ 11.1m | |
| Chief Medical Officer of Autoimmune & Infectious Diseases | 4yrs | no data | 0% $ 0 | |
| Chief Commercial Officer & President of Greater China | 2.58yrs | no data | 0.12% $ 19.2m | |
| Chief Legal Officer | 0.42yr | no data | 0.028% $ 4.5m | |
| Executive VP & Head of Clinical Operations | 7yrs | no data | no data | |
| Senior VP & Head of Business Development | 7yrs | no data | no data | |
| Chief Operating Officer of R&D | 6yrs | no data | no data | |
| VP & Head of Biologics Discovery - China | 2.42yrs | no data | no data | |
| President and Head of Global Development & Oncology | 0.083yr | no data | 0.034% $ 5.5m | |
| Executive Director of Antibody | no data | no data | no data |
2.8yrs
Average Tenure
49yo
Average Age
Experienced Management: ZLAB's management team is considered experienced (2.8 years average tenure).
Board Members
| Name | Position | Tenure | Compensation | Ownership |
|---|---|---|---|---|
| Founder | 7yrs | no data | 1.21% $ 196.0m | |
| President | 4yrs | no data | 0.33% $ 54.4m | |
| Director & Senior Advisor | 4yrs | no data | 0.38% $ 61.9m | |
| Independent Director | 4yrs | no data | 0.068% $ 11.1m | |
| Director | 7yrs | no data | no data | |
| Member of Scientific Advisory Board | 5yrs | no data | no data | |
| Member of Scientific Advisory Board | 4yrs | no data | no data | |
| Independent Director | 2.25yrs | no data | 0.028% $ 4.5m | |
| Member of Scientific Advisory Board | no data | no data | no data | |
| Member of Scientific Advisory Board | 1.92yrs | no data | no data | |
| Independent Director | 2.42yrs | no data | 0.029% $ 4.6m | |
| Member of Scientific Advisory Board | 1.08yrs | no data | no data |
4.0yrs
Average Tenure
63.5yo
Average Age
Experienced Board: ZLAB's board of directors are considered experienced (4 years average tenure).
Ownership
Who are the major shareholders and have insiders been buying or selling?
Insider Trading Volume
Insider Buying: Insufficient data to determine if insiders have bought more shares than they have sold in the past 3 months.
Ownership Breakdown
Dilution of Shares: Shareholders have been diluted in the past year, with total shares outstanding growing by 33%.
Top Shareholders
Company Information
Zai Lab Limited's company bio, employee growth, exchange listings and data sources
Key Information
- Name: Zai Lab Limited
- Ticker: ZLAB
- Exchange: NasdaqGM
- Founded: 2013
- Industry: Biotechnology
- Sector: Pharmaceuticals & Biotech
- Market Cap: US$16.257b
- Shares outstanding: 88.02m
- Website: https://www.zailaboratory.com
Number of Employees
Location
- Zai Lab Limited
- Building 1, Jinchuang Plaza
- 4th Floor
- Shanghai
- 201210
- China
Listings
| Ticker | Exchange | Primary Security | Security Type | Country | Currency | Listed on |
|---|---|---|---|---|---|---|
| ZLAB | NasdaqGM (Nasdaq Global Market) | Yes | Ordinary Shares | US | USD | Sep 2017 |
| 1ZL | DB (Deutsche Boerse AG) | Yes | Ordinary Shares | DE | EUR | Sep 2017 |
| ZLAB N | BMV (Bolsa Mexicana de Valores) | Yes | Ordinary Shares | MX | MXN | Sep 2017 |
| 9688 | SEHK (The Stock Exchange of Hong Kong Ltd.) | Ordinary Shares | HK | HKD | Sep 2020 |
Biography
Zai Lab Limited, a biopharmaceutical company, engages in discovering or licensing, developing, and commercializing proprietary therapeutics that address medical needs in the fields of oncology, autoimmune,...
Company Analysis and Financial Data Status
| Data | Last Updated (UTC time) |
|---|---|
| Company Analysis | 2021/01/20 00:27 |
| End of Day Share Price | 2021/01/19 00:00 |
| Earnings | 2020/06/30 |
| Annual Earnings | 2019/12/31 |
Unless specified all financial data is based on a yearly period but updated quarterly. This is known as Trailing Twelve Month (TTM) or Last Twelve Month (LTM) Data. Learn more here.